Traditionally, HMOs have been studied for their role in beneficially modulating the microbiome, thereby influencing systemic health through immune modulation, gut barrier support, and potential cognitive benefits. However, emerging research reveals that HMOs can be detected systemically in the blood after oral administration, sparking renewed interest in their potential to deliver measurable health outcomes across various life stages.
